9th Annual Biomarkers Congress
Track 7: Second Annual Targeting Diabetes with Novel Therapeutics
Intercontinental Hotel Boston Massachusetts
510 ATLANTIC AVENUE
BOSTON, 02210 • UNITED STATES, MA
http://www.discoveryontarget.com/dbr
Track 7: Second Annual Targeting Diabetes with Novel Therapeutics
Cambridge Healthtech Institute 

Schedule of Presentations:

Tuesday, November 3, 2009
12:30:00 Registration
12:30:00 TARGETING DIABETES AND OBESITY TOGETHER
14:00:00 Chairperson’s Opening Remarks
14:10:00 Modulating Lipid Metabolism Cristina Rondinone
14:40:00 FGF21 for Treatment of Metabolic Diseases Jesper Gromada
15:10:00 Contrave, a New Perspective on Treatment of Obesity and its Implications on Diabetes Dennis Kim
15:40:00 Networking Refreshment Break in the Exhibit Hall
16:20:00 Liver-directed Thyroid Beta Agonist for Targeting Cardio-metabolic Disease Rebecca Taub
16:50:00 Sponsored Presentation (Sponsorship Opportunity Available)
17:20:00 Targeting the Gut for the Treatment of Metabolic Diseases Andrew Swick
17:50:00 Inhibiting Enterocytic MTP for Treatment of Diabetes and Metabolic Syndrome Paul Sweetnam
18:20:00 Close of Day
18:25:00 Announcement
Wednesday, November 4, 2009
07:30:00 Continental Breakfast Breakout Discussions
07:35:00 DRUG DEVELOPMENT CHALLENGES
08:35:00 Chairperson’s Remarks
08:40:00 Development of the First FDA-approved Dopamine Agonist for the Treatment of Type 2 Diabetes Anthony H. Cincotta
09:10:00 Is my Lead Diabetes Candidate “Developable” – Focusing on Biopharmaceutical and Formulation Issues from the Start Akash Jain
09:40:00 Update on Next Generation Incretin-Based Therapies
10:10:00 Networking Coffee Break in the Exhibit Hall
10:55:00 Cardiovascular Outcome Studies of Diabetes Drugs KEYNOTE PRESENTATION Steven E Nissen
11:40:00 PANEL SESSION: Clinical Landscape for New Diabetes Drug Candidates Steven E Nissen
12:25:00 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
12:30:00 CLINICAL CANDIDATES
13:55:00 Chairperson’s Remarks
14:00:00 DB959: A Novel, Dual PPAR delta/gamma Agonist for the Treatment of Type 2 Diabetes Mary Kay Delmedico
14:30:00 ARRY-403: A Glucokinase Activator with Excellent Efficacy in Multiple Models of Type 2 Diabetes Thomas D. Aicher
15:00:00 Networking Ice Cream Refreshment Break in Exhibit Hall (Last Chance for Viewing)
15:40:00 Targeting Sodium-Glucose Co-transporter 2: Knockout and Pharmacology program of LX4211 Melanie K. Shadoan
16:10:00 A Diabetes Clinical Candidate Against a New Target: Soluble Epoxide Hydrolase D. Euan MacIntyre
16:40:00 Clinical Results on a 2nd Generation FBPase Inhibitor (MB07803) for the Treatment of Type 2 Diabetes Barry Gumbiner
17:10:00 Close of Conference
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.